camptothecin has been researched along with Granuloma, Hodgkin in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benoit, LT; Cochran, JH; Emmerton, KK; Lau, UY; Senter, PD; Stevens, NS; Zaval, M | 1 |
| Bartlett, NL; Johnson, JL; Peterson, BA; Ratain, MJ; Wagner-Johnston, N | 1 |
| Fujimoto, K; Kaneki, T; Koizumi, T; Kubo, K; Urushihata, K; Yamaguchi, S | 1 |
| Abu-Ghanem, S; Benharroch, D; Gopas, J; Livneh, E; Oberkovitz, G | 1 |
| Ariyoshi, Y; Furue, H; Kimura, I; Masaoka, T; Ogawa, M; Oguro, M; Ohno, R; Saito, H; Sakai, Y; Yoshida, Y | 1 |
| Eckhardt, SG | 1 |
2 trial(s) available for camptothecin and Granuloma, Hodgkin
| Article | Year |
|---|---|
Phase II study of 9-aminocamptothecin in previously treated lymphomas: results of Cancer and Leukemia Group B 9551.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Drug Resistance, Neoplasm; Female; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Salvage Therapy; Survival Rate | 2009 |
[An early phase II study of CPT-11 (irinotecan hydrochloride) in patients with hematological malignancies].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Drug Administration Schedule; Female; Hodgkin Disease; Humans; Irinotecan; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Nausea; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1994 |
4 other study(ies) available for camptothecin and Granuloma, Hodgkin
| Article | Year |
|---|---|
Lactone Stabilization is Not a Necessary Feature for Antibody Conjugates of Camptothecins.
Topics: Animals; Antibodies; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Hodgkin Disease; Humans; Hydrogen-Ion Concentration; Irinotecan; Lactones; Mice; Mice, SCID; Pharmacokinetics | 2018 |
Successful salvage therapy of irinotecan for relapsed Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Agents; Camptothecin; Enzyme Inhibitors; Hodgkin Disease; Humans; Irinotecan; Male; Radiography; Recurrence; Salvage Therapy; Topoisomerase I Inhibitors | 2002 |
PKCeta expression contributes to the resistance of Hodgkin's lymphoma cell lines to apoptosis.
Topics: Apoptosis; Biopsy; Camptothecin; Caspase 7; Cell Line, Tumor; Cytochromes c; Doxorubicin; Drug Resistance, Neoplasm; Enzyme Activation; Gene Expression Regulation, Neoplastic; Hodgkin Disease; Humans; Poly(ADP-ribose) Polymerases; Protein Kinase C; Reed-Sternberg Cells | 2007 |
Irinotecan: a review of the initial phase I trials.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; France; Hodgkin Disease; Humans; Irinotecan; Japan; Leukemia; Lymphoma, Non-Hodgkin; United States | 1998 |